These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pedigree analysis of a subject with abnormally slow renal elimination of 6-hydroxychlorzoxazone. Vesell ES; Korsunsky Z Pharmacology; 1998 May; 56(5):262-6. PubMed ID: 9597694 [TBL] [Abstract][Full Text] [Related]
5. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. Poloyac SM; Tosheva RT; Gardner BM; Shedlofsky SI; Blouin RA Clin Pharmacol Ther; 1999 Dec; 66(6):554-62. PubMed ID: 10613610 [TBL] [Abstract][Full Text] [Related]
6. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. O'Shea D; Davis SN; Kim RB; Wilkinson GR Clin Pharmacol Ther; 1994 Oct; 56(4):359-67. PubMed ID: 7955797 [TBL] [Abstract][Full Text] [Related]
7. [Determination of chlorzoxazone and its metabolite 6-hydroxychlorzoxazone in plasma by HPLC and their pharmacokinetics]. Li L; Zhang Y Yao Xue Xue Bao; 1998 Oct; 33(10):731-6. PubMed ID: 12016924 [TBL] [Abstract][Full Text] [Related]
8. Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. Burckart GJ; Frye RF; Kelly P; Branch RA; Jain A; Fung JJ; Starzl TE; Venkataramanan R Clin Pharmacol Ther; 1998 Mar; 63(3):296-302. PubMed ID: 9542473 [TBL] [Abstract][Full Text] [Related]
9. [Identification of chlorzoxazone metabolites in human urine (author's transl)]. Twele R; Spiteller G Arzneimittelforschung; 1982; 32(7):759-63. PubMed ID: 6889877 [TBL] [Abstract][Full Text] [Related]
10. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. Frye RF; Stiff DD J Chromatogr B Biomed Appl; 1996 Nov; 686(2):291-6. PubMed ID: 8971612 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. Baek HW; Bae SK; Lee MG; Sohn YT J Pharm Sci; 2006 Nov; 95(11):2452-62. PubMed ID: 16886191 [TBL] [Abstract][Full Text] [Related]
15. A study on the pharmacokinetics of chlorzoxazone in healthy Thai volunteers. Prompila N; Wittayalertpanya S; Komolmit P J Med Assoc Thai; 2007 Jan; 90(1):160-6. PubMed ID: 17621748 [TBL] [Abstract][Full Text] [Related]
16. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Wang Z; Hall SD; Maya JF; Li L; Asghar A; Gorski JC Br J Clin Pharmacol; 2003 Jan; 55(1):77-85. PubMed ID: 12534643 [TBL] [Abstract][Full Text] [Related]
17. Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Chen L; Yang CS Life Sci; 1996; 58(18):1575-85. PubMed ID: 8649187 [TBL] [Abstract][Full Text] [Related]
18. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats. Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723 [TBL] [Abstract][Full Text] [Related]
19. Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. Witt L; Suzuki Y; Hohmann N; Mikus G; Haefeli WE; Burhenne J J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():207-13. PubMed ID: 27300008 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. Ahn CY; Bae SK; Jung YS; Lee I; Kim YC; Lee MG; Shin WG Drug Metab Dispos; 2008 Jul; 36(7):1233-41. PubMed ID: 18378564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]